Shares of MEDNAX Inc (NYSE:MD) have received a consensus recommendation of “Hold” from the eleven research firms that are presently covering the stock. One analyst has rated the stock with a sell recommendation and nine have given a hold recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $65.57.

MD has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Wednesday, March 15th. Robert W. Baird cut shares of MEDNAX from an “outperform” rating to a “neutral” rating and set a $72.00 price objective for the company. in a report on Tuesday, March 21st. TheStreet cut shares of MEDNAX from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th. Bank of America Corp cut shares of MEDNAX from a “buy” rating to an “underperform” rating in a report on Thursday, May 4th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of MEDNAX in a report on Monday, April 10th.

TRADEMARK VIOLATION WARNING: This report was published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/05/26/mednax-inc-md-receives-consensus-rating-of-hold-from-brokerages.html.

In related news, Director Manuel Kadre acquired 21,704 shares of the stock in a transaction on Friday, May 5th. The shares were acquired at an average price of $55.79 per share, with a total value of $1,210,866.16. Following the completion of the transaction, the director now owns 111,255 shares in the company, valued at approximately $6,206,916.45. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Vivian Lopez-Blanco sold 7,778 shares of MEDNAX stock in a transaction dated Friday, May 5th. The stock was sold at an average price of $55.82, for a total transaction of $434,167.96. Following the completion of the sale, the chief financial officer now directly owns 51,319 shares in the company, valued at approximately $2,864,626.58. The disclosure for this sale can be found here. 2.40% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in MD. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of MEDNAX by 5.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $106,000 after buying an additional 77 shares in the last quarter. Ledyard National Bank raised its stake in shares of MEDNAX by 19.0% in the first quarter. Ledyard National Bank now owns 1,725 shares of the company’s stock valued at $120,000 after buying an additional 275 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of MEDNAX by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in shares of MEDNAX by 870.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 2,000 shares of the company’s stock valued at $139,000 after buying an additional 1,794 shares in the last quarter. Finally, Morgan Dempsey Capital Management LLC raised its stake in shares of MEDNAX by 3.6% in the first quarter. Morgan Dempsey Capital Management LLC now owns 2,270 shares of the company’s stock valued at $157,000 after buying an additional 78 shares in the last quarter. 99.16% of the stock is currently owned by institutional investors and hedge funds.

MEDNAX (NYSE:MD) traded down 1.074% during midday trading on Friday, reaching $54.785. 464,755 shares of the company traded hands. The company has a 50 day moving average of $60.04 and a 200-day moving average of $65.89. MEDNAX has a 12-month low of $53.80 and a 12-month high of $76.96. The stock has a market capitalization of $5.06 billion, a P/E ratio of 16.354 and a beta of 0.67.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, May 4th. The company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.01. The firm had revenue of $835.60 million during the quarter, compared to analysts’ expectations of $837.01 million. MEDNAX had a net margin of 10.21% and a return on equity of 13.59%. The business’s revenue was up 11.0% on a year-over-year basis. During the same period last year, the company earned $0.87 earnings per share. Equities analysts anticipate that MEDNAX will post $3.60 EPS for the current fiscal year.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

12 Month Chart for NYSE:MD

Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.